Support liver health

Tertiary referral centres see the worst cases, so 42% is acetaminophen's share of the liver failures that reach those units and never a risk to anyone taking it. Doses in the accidental group were reconstructed from what patients recalled afterwards. The three routes overlap, so one person can sit in all of them and the percentages do not add to a hundred. The narcotic-combination finding is US-specific, since those products are not sold everywhere.

Fourteen days in hospital with every meal provided is not ordinary home use, and 145 people is a small sample for a safety question. The 28-day study used 3 g rather than 4 g, so the two rates are not measuring the same exposure. Its placebo group had an 11% rate of its own, a reminder that this enzyme moves without any drug at all. The 4 g trial ran inside a hydrocodone product development programme, with several industry-affiliated authors.

Low certainty for the encephalopathy benefit, very low for everything else, which is as much the finding as the numbers. No trial compared these preparations against lactulose or rifaximin, the drugs these patients actually get, so nothing here says whether they add to standard care.

People carrying only one copy, and those with the milder H63D variant, showed no excess of anything — and they far outnumber the two-copy group, which is roughly 1 in 150 to 200 people of northern European ancestry. UK Biobank volunteers are healthier than the general population, so these percentages are not population rates. The one-in-ten lifetime figure is for men; the figure for women is substantially lower.

The longest trial in the pool ran 24 weeks. Ten trials contributed to the safety analysis, too few to catch a harm affecting one user in a thousand, and most were funded by manufacturers, who historically under-report adverse events. The four-week study establishes the highest dose formally tested, not a dose any regulator has certified. No trial measured a cardiovascular event.

This was an open treatment series with partly historical comparisons, because withholding an antidote to build a control group was not available. It dates from 1988 and the regimens have changed since, most notably to a shorter two-bag drip. The time bands rest on when people said they took the tablets, which is unreliable after an overdose and missing altogether when doses were spread across days. What survives all of that is the steepness of the gradient, which later guidelines reproduce.

One specialist transplant unit between 1992 and 2008, so these are the most severe cases and the mortality figures are not overdose mortality generally. Ingestion times and patterns were reconstructed from records after the fact. The repeat-dose group did die more often, 37.3% against 27.8%, but that gap did not hold up once age and alcohol misuse were accounted for, so it travels with those rather than clearly causing the worse outcome. Treatment of both patterns has changed since.

None of these three figures is the dose at which injury begins, and the 10,000 mg line is set deliberately below where harm is expected so that clinicians act early. That threshold is also 200 mg per kilogram of body weight wherever that comes to less, so it is lower for a smaller person. It is Australian and New Zealand guidance, and the United Kingdom and United States set their own numbers. The 24,000 mg median describes people who had already reached liver failure, not a dose at which anyone should expect to.

These rates come from patients with severe epilepsy on cannabidiol at 10 to 25mg/kg/day, far above what consumers take. NIH's LiverTox reference gives 21% for the valproate-and-clobazam group where the label gives 30%, attributing its figure to extension studies rather than to these trials.

Thirty-two people finished that trial, and the gap between glutathione and placebo ran close to the significance line, so the honest reading is no proven benefit rather than proven uselessness. The August recall reports came from the pharmacies themselves rather than independent checking, and neither notice names a death or a hospital admission.

There was no control group — the comparison is to historical population figures, not a concurrent placebo arm. Blood was drawn once at 30 days, so a delayed signal would not appear. Participants were recruited through twelve cannabidiol companies, and three of four authors declare industry ties.

The prescription label records liver-enzyme rises that a study of people buying cannabidiol for themselves did not find. Doses differ more than tenfold and so do the people, so the split is about who was studied, not the compound.